Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Helmholtz-Zentrum für Infektionsforschung GmbH currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners across 2 distinct art units. This distribution indicates that each pending matter is being handled by a different technical group within the USPTO.
ELENISTE, PIERRE PAUL is the busiest examiner, with 1 pending action. With 2 pending office actions and 2 distinct examiners, the portfolio's current activity is not concentrated under one person. The presence of 2 distinct art units suggests that the subject matter of the applications is diverse enough to fall into different examination categories within the Biotechnology & Pharmaceuticals field.
The 2 pending office actions will be subject to the specific standards of 2 distinct art units. This lack of overlap means that the company must adapt its prosecution strategy to the different expectations of each unit and examiner. In the Biotechnology & Pharmaceuticals field, this can involve navigating different types of biological or chemical patentability hurdles, requiring a broad approach to portfolio management.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556649 | CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT | ELENISTE, PIERRE PAUL | 15d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636536 | NEW USE OF CYCLIC DINUCLEOTIDES | CHO, DAVID H | 100d overdue |
| 18556649 | CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT | ELENISTE, PIERRE PAUL | 15d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556649 | CITRACONIC ACID AND DERIVATIVES THEREOF FOR USE AS A MEDICAMENT | ELENISTE, PIERRE PAUL | 1622 | §102§103§112 | Final Rejection | 15d overdue | Pending | Oct 20, 2023 |
| 17636536 | NEW USE OF CYCLIC DINUCLEOTIDES | CHO, DAVID H | 1693 | §103Other | Non-Final OA | 100d overdue | Pending | Feb 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHelmholtz-Zentrum für Infektionsforschung GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Pierre Paul Eleniste has the most, with 1 of Helmholtz-Zentrum für Infektionsforschung GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
